CoChat

Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for their efficacy in glycemic control and weight reduction, but patient response is heterogeneous and predictors of weight loss remain insufficiently defined. This 52-week prospective, observational study aimed to identify predictors of weight reduction (≥5% from baseline) in patients with type 2 diabetes mellitus (T2D) undergoing GLP-1RA therapy (semaglutide or dulaglutide, including oral formulations). Methods: A total of 194 adults with T2D initiating GLP-1RA therapy were evaluated at baseline, and after 6, and 12 months of therapy. To identify predictors of weight loss, variables differing between Responders (weight loss ≥5% than baseline) and Non-Responders were evaluated by ROC analysis and tested in univariate and multivariate logistic regression models adjusted for age, gender, GLP-1RA type and dosage. Results: At 6 and 12 months, 58% and 49% of patients, respectively, achieved the primary outcome. Responders at 12 months exhibited elevated BMI, waist circumference, hepatic steatosis indices, fat mass, and insulin levels at baseline, along with reduced muscle-to-fat and muscle-to-visceral adipose tissue ratios. Moreover, female gender, younger age, shorter disease duration, and non-use of metformin prior to enrollment were significantly associated with response. Notably, early response at 6 months strongly predicted 12-month success. Conclusions: Our results highlight a valuable interplay between body composition, liver involvement, and the incretin response, also suggesting a maximal synergistic effect between metformin and GLP-1RAs when treatments are initiated concurrently rather than sequentially. These data provide valuable insights for the development of individualized treatment strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2025.1674308

Cites

Statistics

Figures

Figure 1 Flow diagram illustrating the screening, inclusion, and follow-up of patients enrolled in the study. A total of 850 individuals with type 2 diabetes mellitus were assessed for eligibility. After applying inclusion and exclusion criteria, 194 patients were enrolled and received GLP-1RA therapy. Complete follow-up data were available for 188 patients (96.9%) at 6 months and for 158 patients (81.4%) at 12 months.
Figure 1 Flow diagram illustrating the screening, inclusion, and follow-up of patients enrolled in the study. A total of 850 individuals with type 2 diabetes mellitus were assessed for eligibility. After applying inclusion and exclusion criteria, 194 patients were enrolled and received GLP-1RA therapy. Complete follow-up data were available for 188 patients (96.9%) at 6 months and for 158 patients (81.4%) at 12 months.CC BY · PubMed Central
Figure 2 Variation in the degree of hepatic steatosis detected by ultrasound during the study period. Longitudinal changes in degrees of hepatic steatosis from baseline (T0) to 12 months (T12) of GLP-1RA treatment (McNemar’s test T0 vs T12: p < 0.001). Steatosis was categorized as either absent/mild or moderate/severe based on ultrasonographic assessment at each time point.
Figure 2 Variation in the degree of hepatic steatosis detected by ultrasound during the study period. Longitudinal changes in degrees of hepatic steatosis from baseline (T0) to 12 months (T12) of GLP-1RA treatment (McNemar’s test T0 vs T12: p < 0.001). Steatosis was categorized as either absent/mild or moderate/severe based on ultrasonographic assessment at each time point.CC BY · PubMed Central
Figure 3 Receiver Operating Characteristic (ROC) curves for baseline predictors of weight loss response at 12 months. The optimal cut-off points for each variable were identified using Youden’s Index. Sensitivity and specificity values correspond to the optimal cut-off points. AUC, Area Under the Curve; BMI, Body Mass Index; WC, Waist Circumference; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; GGT, Gamma-Glutamyl Transferase; ALT, Alanine Aminotransferase; FLI, Fatty Liver Index; FM, Fat Mass; FMI, Fat Mass Index; FFM, Fat-Free Mass; SMM, Skeletal Muscle Mass; VAT, Visceral Adipose Tissue.
Figure 3 Receiver Operating Characteristic (ROC) curves for baseline predictors of weight loss response at 12 months. The optimal cut-off points for each variable were identified using Youden’s Index. Sensitivity and specificity values correspond to the optimal cut-off points. AUC, Area Under the Curve; BMI, Body Mass Index; WC, Waist Circumference; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; GGT, Gamma-Glutamyl Transferase; ALT, Alanine Aminotransferase; FLI, Fatty Liver Index; FM, Fat Mass; FMI, Fat Mass Index; FFM, Fat-Free Mass; SMM, Skeletal Muscle Mass; VAT, Visceral Adipose Tissue.CC BY · PubMed Central
Figure 4 Forest Plot of Quantitative Predictors for ≥5% Body Weight Loss at 12 Months. Each variable was independently tested in a separate binary logistic regression model, adjusted for age, gender (except when analyzing age, adjusted for gender only), type and dosage of GLP-1RA used. All predictors are modeled as dichotomous variables. OR, Odds Ratio; CI, Confidence Interval; SMM, Skeletal Muscle Mass; FM, Fat Mass; VAT, Visceral Adipose Tissue; FFM, Fat-Free Mass; BMI, Body Mass Index; FLI, Fatty Liver Index; GGT, Gamma-Glutamyl Transferase; FMI, Fat Mass Index; WC, Waist Circumference.
Figure 4 Forest Plot of Quantitative Predictors for ≥5% Body Weight Loss at 12 Months. Each variable was independently tested in a separate binary logistic regression model, adjusted for age, gender (except when analyzing age, adjusted for gender only), type and dosage of GLP-1RA used. All predictors are modeled as dichotomous variables. OR, Odds Ratio; CI, Confidence Interval; SMM, Skeletal Muscle Mass; FM, Fat Mass; VAT, Visceral Adipose Tissue; FFM, Fat-Free Mass; BMI, Body Mass Index; FLI, Fatty Liver Index; GGT, Gamma-Glutamyl Transferase; FMI, Fat Mass Index; WC, Waist Circumference.CC BY · PubMed Central
Figure 5 Forest Plot of Qualitative Predictors for ≥5% Body Weight Loss at 12 Months. Each variable was tested in a separate binary logistic regression model adjusted for age, gender (except when analyzing gender itself, which was only adjusted for age), type and dosage of GLP-1RA. All odds ratios (OR) are reported with corresponding 95% confidence intervals and p-values.
Figure 5 Forest Plot of Qualitative Predictors for ≥5% Body Weight Loss at 12 Months. Each variable was tested in a separate binary logistic regression model adjusted for age, gender (except when analyzing gender itself, which was only adjusted for age), type and dosage of GLP-1RA. All odds ratios (OR) are reported with corresponding 95% confidence intervals and p-values.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 39 · Cited by 12

Metadata

Authors
Vozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., Lavarra, V., Maggipinto, R., Portacci, A., Tortorella, C., Moschetta, A., & Piazzolla, G.
Affiliations
University of Bari Aldo Moro (IT)
Corresponding author
Piazzolla, Giuseppina
Venue
Frontiers in Endocrinology
Published
2025-09-25
Volume
16
Pages
1674308-1674308
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4414520645
Cited by
12
References
39
Citations by year
2026: 12
FWCI
8.12
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, GLP-1 receptor agonists, weight loss, predictors of treatment response, semaglutide, dulaglutide, body composition, hepatic steatosis, insulin, metformin, sex differences, disease duration, visceral adipose tissue
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Prognosis, Prospective Studies, Recombinant Fusion Proteins, Weight Loss, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study. https://app.cochat.ai/papers/10.3389/fendo.2025.1674308
The paper
Vozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., Lavarra, V., Maggipinto, R., Portacci, A., Tortorella, C., Moschetta, A., & Piazzolla, G. (2025). Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1674308

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.